PaTHway: A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism

• Sponsor: Ascendis Pharma Bone Diseases A/S (Industry)
• Overall Status: Active, not recruiting
• CT.gov ID: NCT04701203
• Collaborator: (none)
• Enrollment: 82
• Locations: 21
• Arms: 2
• Anticipated Duration (Months): 46.5
• Patients Per Site: 3.9
• Patients Per Site Per Month: 0.1

Study Details

Study Description

Brief Summary

During the first 26 weeks of the trial, participants will be randomly assigned to one of two groups: one group will receive TransCon PTH and one group will receive placebo. All subjects will start with a fixed dose of study drug and will be individually and progressively titrated to an optimal dose over a 10 week period, followed by an individualized dosing period up to 16 weeks. TransCon PTH or placebo will be administered as a subcutaneous injection using a pre-filled injection pen. Neither trial participants nor their doctors will know who has been assigned to each group. After the 26 weeks, participants will continue in the trial as part of a long-term extension study. During the extension, all participants will receive TransCon PTH, with the dose adjusted to their individual needs. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Germany, and Denmark.

Condition or Disease	Intervention/Treatment	Phase
Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseases	Combination Product: TransCon PTH; Combination Product: Placebo	Phase 3

Study Design

• Study Type: Interventional
• Actual Enrollment: 82 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: Double-blind, placebo controlled, parallel group with subjects randomized into two treatment groups (3:1): TransCon PTH at a starting dose of 18 mcg/day, and placebo for TransCon PTHDouble-blind, placebo controlled, parallel group with subjects randomized into two treatment groups (3:1): TransCon PTH at a starting dose of 18 mcg/day, and placebo for TransCon PTH
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: PaTHway TRIAL: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial, With an Open-Label Extension, Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Subcutaneously Daily in Adults With Hypoparathyroidism
• Actual Study Start Date: Feb 16, 2021
• Actual Primary Completion Date: Jan 12, 2022
• Anticipated Study Completion Date: Jan 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: TransCon PTH TransCon PTH at a starting dose of 18 mcg delivered once daily by subcutaneous injection	Combination Product: TransCon PTH; TransCon PTH drug product is supplied as a solution with a concentration of 0.3 mg PTH(1-34)/mL in a single-patient-use prefilled pen intended for subcutaneous injection.
Placebo Comparator: Placebo Placebo for TransCon PTH delivered once daily by subcutaneous injection	Combination Product: Placebo; Placebo is supplied as a solution containing the formulation buffer for TransCon PTH in a single-patient-use prefilled pen intended for subcutaneous injection.

Outcome Measures

Primary Outcome Measures

1. Efficacy - Primary endpoint [26 weeks]

   The proportion of subjects with albumin-adjusted sCa within the normal range, and independence from active vitamin D, and independence from therapeutic doses of calcium (i.e., taking calcium supplements ≤600 mg/day), and no increase in prescribed study drug within 4 weeks prior to Week 26 visit

Secondary Outcome Measures

1. Change from baseline in HPES Symptom - Physical Domain score [26 weeks]

   Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Physical Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment

2. Change from baseline in HPES Symptom - Cognitive Domain score [26 weeks]

   Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Symptom - Cognitive Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment

3. Change from baseline in HPES Impact - Physical Functioning Domain score [26 weeks]

   Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Physical Functioning Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment

4. Change from baseline in HPES Impact - Daily Life Domain score [26 weeks]

   Change from baseline in Hypoparathyroidism Patient Experience Scale (HPES) Impact - Daily Life Domain score, a disease-specific patient reported outcome, at 26 weeks of treatment

5. Change from baseline in SF-36 Physical Functioning subscale score [26 weeks]

   Change from baseline in the 36-item Short Form Survey (SF-36) Physical Functioning subscale score, a generic health survey, at 26 weeks of treatment

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Males and females, ≥18 years of age

2. Subjects with postsurgical chronic HP, or auto-immune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is established based on historic hypocalcemia in the setting of inappropriately low serum PTH levels

3. Requirement for doses of SoC (e.g., calcitriol, alfacalcidol, calcium supplements) at or above a minimum threshold:

• For countries other than Japan: requirement for a dose of calcitriol ≥0.5 μg/day, or alfacalcidol ≥1.0 μg/day and (elemental) calcium ≥800 mg/day (e.g., calcium citrate, calcium carbonate etc.) for at least 12 weeks prior to Screening. In addition, the dose of calcitriol, or alfacalcidol, or calcium should be stable for at least 5 weeks prior to Screening

• For Japan: requirement for a dose of calcitriol ≥1.0 μg/day, or alfacalcidol ≥2.0 μg/day for at least 12 weeks prior to Screening. In addition, the dose of calcitriol or alfacalcidol should be stable for at least 5 weeks prior to Screening. In Japan only (due to local practice and dietary patterns), there is no requirement to exceed a minimum dose of calcium supplements

1. Optimization of supplements prior to randomization to achieve the target serum levels of:

• 25(OH) vitamin D levels of 20-80 ng/mL (49-200 nmol/L) and

• Magnesium level in the normal range, or just below the normal range and

• Albumin-adjusted or ionized sCa level in the normal range, or just below the normal range

1. The subject demonstrates a 24-hour uCa excretion of ≥125 mg/24h (on a sample collected within 52 weeks prior to Screening or during the Screening Period)

2. BMI 17- 40 kg/m2 at Screening

3. If ≤25 years of age, radiological evidence of epiphyseal closure based on X-ray of nondominant wrist and hand

4. Thyroid-stimulating hormone (TSH) within normal laboratory limits within the 6 weeks prior to Visit 1; if on suppressive therapy for a history of thyroid cancer, TSH level must be ≥0.2 mIU/mL

5. If treated with thyroid hormone replacement therapy, the dose must have been stable for at least 5 weeks prior to Screening

6. eGFR ≥30 mL/min/1.73 m2 during Screening

7. Able to perform daily subcutaneous self-injections of study drug (or have a designee to perform injections) via a pre-filled injection pen

8. Able and willing to provide written and signed informed consent in accordance with GCP

Exclusion Criteria:

1. Impaired responsiveness to PTH (pseudohypoparathyroidism) which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia

2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP, such as active hyperthyroidism; Paget disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1C >9%, documented HbA1C result drawn within 12 weeks prior to Screening is acceptable); severe and chronic liver, or renal disease; Cushing syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobility; active malignancy (other than low-risk well differentiated thyroid cancer or basal cell skin cancer); active hyperparathyroidism; parathyroid carcinoma within 5 years prior to Screening; acromegaly; or multiple endocrine neoplasia types 1 and 2

3. High risk thyroid cancer within 2 years, requiring suppression of TSH <0.2 mIU/mL

4. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin >30 μg/day, or systemic corticosteroids (other than as replacement therapy)

5. Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1

6. Use of PTH-like drugs (whether commercially available or through participation in an investigational trial), including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH or PTH-related protein, within 4 weeks prior to Screening

7. Use of other drugs known to influence calcium and bone metabolism, such as calcitonin, fluoride tablets (>0.5 mg/day), strontium, or cinacalcet hydrochloride, within 12 weeks prior to Screening

8. Use of osteoporosis therapies known to influence calcium and bone metabolism, i.e., bisphosphonate (oral or intravenous [IV]), denosumab, raloxifene, or romosozumab therapies within 2 years prior to Screening

9. Non-hypocalcemic seizure disorder with a history of a seizure within 26 weeks prior to Screening

10. Increased risk for osteosarcoma, such as those with Paget's disease of bone or unexplained elevations of alkaline phosphatase, hereditary disorders predisposing to osteosarcoma, or with a prior history of substantial external beam or implant radiation therapy involving the skeleton

11. Pregnant or lactating women

12. Male who has a female partner who intends to become pregnant or is of childbearing potential and is unwilling to use adequate contraceptive methods during the trial

13. Diagnosed drug or alcohol dependence within 3 years prior to Screening

14. Disease processes that adversely affect gastrointestinal absorption, including but not limited to short bowel syndrome, significant small bowel resection, gastric bypass, tropical sprue, active celiac disease, active ulcerative colitis, active Crohn's disease, gastroparesis and AIRE gene mutations with malabsorption

15. Chronic or severe cardiac disease within 26 weeks prior to Screening including but not limited to congestive heart failure, myocardial infarction, severe or uncontrolled arrhythmias, bradycardia (resting heart rate <48 beats/minute, unless chronic and asymptomatic), symptomatic hypotension or systolic BP <80 mm Hg or diastolic <40 mm Hg or poorly controlled hypertension (systolic BP >165 mm Hg or diastolic >95 mm Hg). In the absence of a prior history of hypertension, an isolated BP >165/95 in the setting of white coat hypertension/anxiety may not be exclusionary and a measurement can be repeated prior to randomization

16. Cerebrovascular accident within 5 years prior to Screening

17. Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout. Subjects with asymptomatic renal stones are permitted

18. Participation in any other interventional trial in which receipt of investigational drug or device occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug (whichever comes first) prior to Screening

19. Any disease or condition that, in the opinion of the investigator, may require treatment or make the subject unlikely to fully complete the trial, or any condition that presents undue risk from the investigational product or procedures, including treated malignancies that are likely to recur within the approximate 3.5-year duration of the trial

20. Known allergy or sensitivity to PTH or any of the excipients [metacresol, mannitol, succinic acid, NaOH/(HCl)]

21. Likely to be non-compliant with respect to trial conduct

22. Any other reason that in the opinion of the investigator would prevent the subject from completing participation or following the trial schedule

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Ascendis Pharma Investigational Site	San Francisco	California	United States	94143
2	Ascendis Pharma Investigational Site	Chicago	Illinois	United States	60637
3	Ascendis Pharma Investigational Site	Rochester	Minnesota	United States	55905
4	Ascendis Pharma Investigational Site	Reno	Nevada	United States	89511
5	Ascendis Pharma Investigational Site	New York	New York	United States	10032
6	Ascendis Pharma Investigational Site	Greenville	North Carolina	United States	27834
7	Ascendis Pharma Investigational Site	Austin	Texas	United States	78731
8	Ascendis Pharma Investigational Site	Fort Worth	Texas	United States	76132
9	Ascendis Pharma Investigational Site	Spokane	Washington	United States	99204
10	Ascendis Pharma Investigational Site	Halifax	Nova Scotia	Canada	B3H 2Y9
11	Ascendis Pharma Investigational Site	Oakville	Ontario	Canada	L6M 1M1
12	Ascendis Pharma Investigational Site	Québec	Quebec	Canada	G1V 4G2
13	Ascendis Pharma Investigational Site	København	Hovedstaden	Denmark	2100
14	Ascendis Pharma Investigational Site	Aarhus	Midtjylland	Denmark	8200
15	Ascendis Pharma Investigational Site	Dresden	Sachsen	Germany	01307
16	Ascendis Pharma Investigational Site	Szeged	Csongrad	Hungary	6720
17	Ascendis Pharma Investigational Site	Budapest		Hungary	1083
18	Ascendis Pharma Investigational Site	Bologna	Emilia-Romagna	Italy	40138
19	Ascendis Pharma Investigational Site	Roma	Lazio	Italy	00128
20	Ascendis Pharma Investigational Site	Pisa	Piacenza	Italy	56126
21	Ascendis Pharma Investigational Site	Oslo		Norway	0176

Sponsors and Collaborators

• Ascendis Pharma Bone Diseases A/S

Investigators

• Study Director: Aimee D Shu, MD, Ascendis Pharma A/S North American Medical Monitor/Medical Expert
• Study Director: Michael Beckert, MD, Ascendis Pharma A/S European Medical Monitor/Medical Expert

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Ascendis Pharma Bone Diseases A/S
• ClinicalTrials.gov Identifier: NCT04701203
• Other Study ID Numbers: TCP-304; 2020-003380-26
• First Posted: Jan 8, 2021
• Last Update Posted: Aug 9, 2022
• Last Verified: Aug 1, 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Ascendis Pharma Bone Diseases A/S: Hypoparathyroidism; Parathyroid Hormone; TransCon PTH; PTH(1-34); Prodrug; Sustained Release; Parathyroid Hormone Replacement Therapy
• Additional relevant MeSH terms: Hypoparathyroidism; Endocrine System Diseases; Parathyroid Diseases

Study Results

No Results Posted as of Aug 9, 2022